Research graph
References from Dual Targeted Therapy as a Treatment Strategy for Refractory Psoriatic Arthritis: Real‐World Effectiveness and Safety From a Prospective Cohort. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1093/rheumatology/keaa030
10.1093/rheumatology/keaa030 · External reference
10.1136/ard-2023-224916
10.1136/ard-2023-224916 · External reference
10.1007/s40744-023-00574-w
10.1007/s40744-023-00574-w · External reference
10.1002/art.42780
10.1002/art.42780 · External reference
10.1093/rap/rkae074
10.1093/rap/rkae074 · External reference
10.1136/rmdopen-2023-003809
10.1136/rmdopen-2023-003809 · External reference
10.1093/rheumatology/keaf207
10.1093/rheumatology/keaf207 · External reference
10.1038/s41584-025-01329-3
10.1038/s41584-025-01329-3 · External reference
10.1016/j.ard.2025.10.002
10.1016/j.ard.2025.10.002 · External reference
10.1016/j.clinthera.2023.05.010
10.1016/j.clinthera.2023.05.010 · External reference
10.1016/j.berh.2025.102090
10.1016/j.berh.2025.102090 · External reference
10.1016/s2665-9913(25)00289-9
10.1016/s2665-9913(25)00289-9 · External reference
10.1016/s0140-6736(15)00347-5
10.1016/s0140-6736(15)00347-5 · External reference
10.1016/s2665-9913(22)00028-5
10.1016/s2665-9913(22)00028-5 · External reference
10.1016/s2665-9913(22)00008-x
10.1016/s2665-9913(22)00008-x · External reference
10.1016/s2665-9913(25)00156-0
10.1016/s2665-9913(25)00156-0 · External reference
10.1016/s2665-9913(25)00223-1
10.1016/s2665-9913(25)00223-1 · External reference
10.1002/art.20221
10.1002/art.20221 · External reference
10.3389/fimmu.2023.1283251
10.3389/fimmu.2023.1283251 · External reference
10.1097/rhu.0000000000001767
10.1097/rhu.0000000000001767 · External reference
10.1136/annrheumdis-2021-221812
10.1136/annrheumdis-2021-221812 · External reference
10.1016/s2468-1253(22)00427-7
10.1016/s2468-1253(22)00427-7 · External reference
A phase 2a, multicenter, randomized, double‐blind study evaluating the efficacy and safety of subcutaneously administered guselkumab and golimumab combination therapy in participants with active psoriatic arthritis
2025 · External reference
10.1002/art.21972
10.1002/art.21972 · External reference
10.1093/rheumatology/keq262
10.1093/rheumatology/keq262 · External reference
10.1016/j.autrev.2025.103865
10.1016/j.autrev.2025.103865 · External reference
10.1007/s40744-022-00461-w
10.1007/s40744-022-00461-w · External reference
10.1038/s41584-025-01229-6
10.1038/s41584-025-01229-6 · External reference
10.1038/s41584-022-00798-0
10.1038/s41584-022-00798-0 · External reference
10.3899/jrheum.220310
10.3899/jrheum.220310 · External reference
10.1038/s41584-024-01083-y
10.1038/s41584-024-01083-y · External reference
10.5041/rmmj.10494
10.5041/rmmj.10494 · External reference
10.1186/s12913-023-09595-1
10.1186/s12913-023-09595-1 · External reference
10.1093/rheumatology/keac078
10.1093/rheumatology/keac078 · External reference
10.3899/jrheum.200128
10.3899/jrheum.200128 · External reference
10.3899/jrheum.171411
10.3899/jrheum.171411 · External reference
10.55563/clinexprheumatol/2pmt67
10.55563/clinexprheumatol/2pmt67 · External reference
10.1016/j.clinthera.2023.04.005
10.1016/j.clinthera.2023.04.005 · External reference
10.1186/s42358-024-00414-7
10.1186/s42358-024-00414-7 · External reference
10.1007/s10067-023-06605-9
10.1007/s10067-023-06605-9 · External reference
10.1136/rmdopen-2025-005785
10.1136/rmdopen-2025-005785 · External reference
